Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 26, 2003Diabetes/Metabolism Research and ReviewsOpen Access

Left‐ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR‐α or ‐γ agonists in a type 2 diabetic animal model

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does treatment with PPAR-alpha or -gamma agonists prevent left-ventricular diastolic dysfunction in a type 2 diabetic animal model?

Population

Male Otsuka Long-Evans Tokushima Fatty rats, a model of type 2 diabetes, aged 28 weeks. Male Long-Evans…

Comparison

Pioglitazone or fenofibrate for 10 weeks vs Untreated OLETF rats

Design

Preclinical

Follow-up

10 weeks

Authors

SKSoo Kyung KimZZZheng Shan ZhaoYLYong-Jik Lee

Discussion

Loading...

Member takes

Overview

Hypothesis-generating for PPAR agonists in diabetic diastolic dysfunction; human trials needed before any clinical consideration.

Structured PICO

Does treatment with PPAR-alpha or -gamma agonists prevent left-ventricular diastolic dysfunction in a type 2 diabetic animal model?

P
Population
Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of type 2 diabetes, aged 28 weeks. Male Long-Evans Tokushima Otsuka (LETO) rats were used as nondiabetic control.
I
Intervention
Pioglitazone (10 mg/kg/d) or fenofibrate (150 mg/kg/d) for 10 weeks
C
Comparator
Untreated OLETF rats
O
Outcome
Left-ventricular diastolic dysfunction (measured by Doppler echocardiography parameters DTE and E/A ratio) and malonyl-CoA decarboxylase (MCD) activity at the myocardiumsurrogate

Chronic treatment with PPAR-alpha or -gamma agonists prevented left-ventricular diastolic dysfunction in a type 2 diabetic rat model, associated with increased myocardial MCD activity.

Cite This Study

Kim et al. (2003) studied this question.

synapsesocial.com/papers/6a911bfa02b8c0248acaed49https://doi.org/10.1002/dmrr.410
View Full Paper
Ask AI
Bookmark
Share